Pfizer takes Vyndaqel copay fight to Supreme Court, decrying 'staggeringly overbroad' anti-kickback rule

After two legal defeats, Pfizer is taking its copay assistance lawsuit for costly rare heart disease drug tafamidis to the Supreme Court. Once again, the company is challenging the U.S. Department of Health and Human Services’ (HHS') interpretation of anti-kickback law.